Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulranumab as Adjunctive Therapy in Osteoarthritis of the Hip or Knee
NCT02336685Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2015
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of fulranumab in osteoarthritis (OA) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Western Ontario and McMaster University Arthritis Index Pain Subscale Score at 16 weeks, Western Ontario and McMaster University Arthritis Index Physical Function Subscale Score at 16 weeks and 1 more. Started Jul 2015; status: completed.
02
Drugs
fulranumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02336685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02336685.